Skip to main content
Erschienen in: Pathology & Oncology Research 2/2019

08.11.2018 | Original Article

Triiodothyronine Promotes Cell Proliferation of Breast Cancer via Modulating miR-204/Amphiregulin

verfasst von: Li Zhang, Fengxiang Zhang, Yanxin Li, Xiangjun Qi, Yaming Guo

Erschienen in: Pathology & Oncology Research | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer (BC) severely threatens women’s life, and Triiodothyronine (T3) shows a positive role on BC cell proliferation, while the potential mechanism underlying it is still unclear. T3 was used to stimulate BC cell lines MCF-7 and T47-D. Real-time PCR was performed to determine the expression of miRNAs, while western blot was used to measure protein expression of Amphiregulin (AREG), AKT and p-AKT. The interaction between miR-204 and AREG was determined using luciferase reporter assay. MTT was performed to detect cell viability. The expression of miR-204 was decreased, while AREG and p-AKT was increased in T3 stimulated BC cell lines. T3 stimulation promoted cell viability. miR-204 targets AREG to regulate its expression. T3 promoted expression of AREG and p-AKT, while miR-204 overexpression reversed the effect of T3, however, pcDNA-AREG transfection abolished the effect of miR-204 mimic. T3 promoted cell viability of BC cells via modulating the AKT signaling pathway. The detailed mechanism was that the down-regulated miR-204 that induced by T3 stimulation promoted the expression of AREG, the up-regulated AREG activated AKT signaling pathway, while the activated AKT signaling promoted cell proliferation.
Literatur
1.
Zurück zum Zitat Galton VA, Schneider MJ, Clark AS, St Germain DL (2009) Life without thyroxine to 3,5,3′-triiodothyronine conversion: studies in mice devoid of the 5′-deiodinases. Endocrinology 150:2957–2963CrossRefPubMedPubMedCentral Galton VA, Schneider MJ, Clark AS, St Germain DL (2009) Life without thyroxine to 3,5,3′-triiodothyronine conversion: studies in mice devoid of the 5′-deiodinases. Endocrinology 150:2957–2963CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeold A, Bianco AC (2008) Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 29:898–938CrossRefPubMedPubMedCentral Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeold A, Bianco AC (2008) Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev 29:898–938CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Saraiva PP, Figueiredo NB, Padovani CR, Brentani MM, Nogueira CR (2005) Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res 38:761–765CrossRefPubMed Saraiva PP, Figueiredo NB, Padovani CR, Brentani MM, Nogueira CR (2005) Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res 38:761–765CrossRefPubMed
4.
Zurück zum Zitat Dinda S, Sanchez A, Moudgil V (2002) Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 21:761–768CrossRefPubMed Dinda S, Sanchez A, Moudgil V (2002) Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells. Oncogene 21:761–768CrossRefPubMed
5.
Zurück zum Zitat Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI (2006) Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 17:60–64CrossRefPubMed Conde I, Paniagua R, Zamora J, Blanquez MJ, Fraile B, Ruiz A, Arenas MI (2006) Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 17:60–64CrossRefPubMed
6.
Zurück zum Zitat Hall LC, Salazar EP, Kane SR, Liu N (2008) Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 109:57–66CrossRefPubMed Hall LC, Salazar EP, Kane SR, Liu N (2008) Effects of thyroid hormones on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 109:57–66CrossRefPubMed
7.
Zurück zum Zitat Rohini M, Gokulnath M, Miranda PJ, Selvamurugan N (2018) MiR-590-3p inhibits proliferation and promotes apoptosis by targeting activating transcription factor 3 in human breast Cancer cells. Biochimie 154:10–18CrossRefPubMed Rohini M, Gokulnath M, Miranda PJ, Selvamurugan N (2018) MiR-590-3p inhibits proliferation and promotes apoptosis by targeting activating transcription factor 3 in human breast Cancer cells. Biochimie 154:10–18CrossRefPubMed
8.
Zurück zum Zitat Yan L, Yu MC, Gao GL, Liang HW, Zhou XY, Zhu ZT, Zhang CY, Wang YB, Chen X (2018) MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. J Cell Biochem 119:8773–8783CrossRefPubMed Yan L, Yu MC, Gao GL, Liang HW, Zhou XY, Zhu ZT, Zhang CY, Wang YB, Chen X (2018) MiR-125a-5p functions as a tumour suppressor in breast cancer by downregulating BAP1. J Cell Biochem 119:8773–8783CrossRefPubMed
9.
Zurück zum Zitat Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:202–210CrossRefPubMed Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R (2008) The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 10:202–210CrossRefPubMed
10.
Zurück zum Zitat Chen J, Wang BC, Tang JH (2012) Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol 106:260–266CrossRefPubMed Chen J, Wang BC, Tang JH (2012) Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol 106:260–266CrossRefPubMed
11.
Zurück zum Zitat Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S (2014) miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res 74:4145–4156CrossRefPubMed Dinami R, Ercolani C, Petti E, Piazza S, Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, Benetti R, Mottolese M, Schneider C, Blandino G, Schoeftner S (2014) miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Res 74:4145–4156CrossRefPubMed
12.
Zurück zum Zitat Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ (2011) Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130:663–679CrossRefPubMedPubMedCentral Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ (2011) Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130:663–679CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM (2012) Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6:458–472CrossRefPubMedPubMedCentral Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, Tortoreto M, Sasso M, Plantamura I, Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM (2012) Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol 6:458–472CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ, Huang X, Zhao J, Gu B, Zheng GX, Yang AG, Jia LT (2014) MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer 135:1356–1368CrossRefPubMed Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ, Huang X, Zhao J, Gu B, Zheng GX, Yang AG, Jia LT (2014) MiR-200c suppresses TGF-beta signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J Cancer 135:1356–1368CrossRefPubMed
15.
Zurück zum Zitat Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J, Cheng L, Fan Z, Yuan B, Tian P, Zheng X, Yu C, Ye Q, Lv Z (2014) miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun 445:314–319CrossRefPubMed Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J, Cheng L, Fan Z, Yuan B, Tian P, Zheng X, Yu C, Ye Q, Lv Z (2014) miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun 445:314–319CrossRefPubMed
16.
Zurück zum Zitat Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L (2014) Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol 7:3287–3292PubMedPubMedCentral Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L (2014) Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol 7:3287–3292PubMedPubMedCentral
17.
Zurück zum Zitat Shen SQ, Huang LS, Xiao XL, Zhu XF, Xiong DD, Cao XM, Wei KL, Chen G, Feng ZB (2017) miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. Oncol Rep 38:368–376CrossRefPubMed Shen SQ, Huang LS, Xiao XL, Zhu XF, Xiong DD, Cao XM, Wei KL, Chen G, Feng ZB (2017) miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1. Oncol Rep 38:368–376CrossRefPubMed
18.
Zurück zum Zitat Willmarth NE, Ethier SP (2008) Amphiregulin as a novel target for breast cancer therapy. J Mammary Gland Biol Neoplasia 13:171–179CrossRefPubMed Willmarth NE, Ethier SP (2008) Amphiregulin as a novel target for breast cancer therapy. J Mammary Gland Biol Neoplasia 13:171–179CrossRefPubMed
19.
Zurück zum Zitat Figueiredo NB, Cestari SH, Conde SJ, Luvizotto RA, De Sibio MT, Perone D, Katayama ML, Carraro DM, Brentani HP, Brentani MM, Nogueira CR (2014) Estrogen-responsive genes overlap with triiodothyronine-responsive genes in a breast carcinoma cell line. ScientificWorldJournal 2014:969404PubMedPubMedCentral Figueiredo NB, Cestari SH, Conde SJ, Luvizotto RA, De Sibio MT, Perone D, Katayama ML, Carraro DM, Brentani HP, Brentani MM, Nogueira CR (2014) Estrogen-responsive genes overlap with triiodothyronine-responsive genes in a breast carcinoma cell line. ScientificWorldJournal 2014:969404PubMedPubMedCentral
20.
Zurück zum Zitat Wang X, Masri S, Phung S, Chen S (2008) The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res 68:2259–2265CrossRefPubMedPubMedCentral Wang X, Masri S, Phung S, Chen S (2008) The role of amphiregulin in exemestane-resistant breast cancer cells: evidence of an autocrine loop. Cancer Res 68:2259–2265CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kondapaka SB, Fridman R, Reddy KB (1997) Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70:722–726CrossRefPubMed Kondapaka SB, Fridman R, Reddy KB (1997) Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 70:722–726CrossRefPubMed
22.
Zurück zum Zitat Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G (2012) miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 3:e423CrossRefPubMedPubMedCentral Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G (2012) miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 3:e423CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Xia Z, Liu F, Zhang J, Liu L (2015) Decreased expression of MiRNA-204-5p contributes to glioma progression and promotes glioma cell growth, migration and invasion. PLoS One 10:e0132399CrossRefPubMedPubMedCentral Xia Z, Liu F, Zhang J, Liu L (2015) Decreased expression of MiRNA-204-5p contributes to glioma progression and promotes glioma cell growth, migration and invasion. PLoS One 10:e0132399CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Wu ZY, Wang SM, Chen ZH, Huv SX, Huang K, Huang BJ, Du JL, Huang CM, Peng L, Jian ZX, Zhao G (2015) MiR-204 regulates HMGA2 expression and inhibits cell proliferation in human thyroid cancer. Cancer Biomark 15:535–542CrossRefPubMed Wu ZY, Wang SM, Chen ZH, Huv SX, Huang K, Huang BJ, Du JL, Huang CM, Peng L, Jian ZX, Zhao G (2015) MiR-204 regulates HMGA2 expression and inhibits cell proliferation in human thyroid cancer. Cancer Biomark 15:535–542CrossRefPubMed
25.
Zurück zum Zitat Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan H, Xu S (2015) Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med 36:1720–1726CrossRefPubMed Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan H, Xu S (2015) Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med 36:1720–1726CrossRefPubMed
27.
Zurück zum Zitat Zhou S, Li S, Zhang W, Tong H, Li S, Yan Y (2018) MiR-139 promotes differentiation of bovine skeletal muscle-derived satellite cells by regulating DHFR gene expression. J Cell Physiol 234(1):632–641 Zhou S, Li S, Zhang W, Tong H, Li S, Yan Y (2018) MiR-139 promotes differentiation of bovine skeletal muscle-derived satellite cells by regulating DHFR gene expression. J Cell Physiol 234(1):632–641
28.
Zurück zum Zitat Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522–1533CrossRefPubMed Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64:1522–1533CrossRefPubMed
29.
Zurück zum Zitat Ghazanchaei A, Mansoori B, Mohammadi A, Biglari A, Baradaran B (2018) Restoration of miR-152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT-ERK pathway in colorectal cancer. J Cell Physiol 234:769–776CrossRefPubMed Ghazanchaei A, Mansoori B, Mohammadi A, Biglari A, Baradaran B (2018) Restoration of miR-152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT-ERK pathway in colorectal cancer. J Cell Physiol 234:769–776CrossRefPubMed
30.
Zurück zum Zitat Li X, Liu H, Wang J, Qin J, Bai Z, Chi B, Yan W, Chen X (2018) Curcumol induces cell cycle arrest and apoptosis by inhibiting IGF-1R/PI3K/Akt signaling pathway in human nasopharyngeal carcinoma CNE-2 cells. Phytother Res 32(11):2214–2225 Li X, Liu H, Wang J, Qin J, Bai Z, Chi B, Yan W, Chen X (2018) Curcumol induces cell cycle arrest and apoptosis by inhibiting IGF-1R/PI3K/Akt signaling pathway in human nasopharyngeal carcinoma CNE-2 cells. Phytother Res 32(11):2214–2225
31.
Zurück zum Zitat Kim JW, Kim DK, Min A, Lee KH, Nam HJ, Kim JH, Kim JS, Kim TY, Im SA, Park IA (2016) Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer. J Cancer Res Clin Oncol 142(1):157–165 Kim JW, Kim DK, Min A, Lee KH, Nam HJ, Kim JH, Kim JS, Kim TY, Im SA, Park IA (2016) Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer. J Cancer Res Clin Oncol 142(1):157–165
Metadaten
Titel
Triiodothyronine Promotes Cell Proliferation of Breast Cancer via Modulating miR-204/Amphiregulin
verfasst von
Li Zhang
Fengxiang Zhang
Yanxin Li
Xiangjun Qi
Yaming Guo
Publikationsdatum
08.11.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 2/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0525-2

Weitere Artikel der Ausgabe 2/2019

Pathology & Oncology Research 2/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.